A small-molecule TREM2 agonist for Alzheimer’s disease
Preclinical analysis and a phase 1 trial support VG-3927 as a promising drug candidate for Alzheimer’s disease, demonstrating successful penetration of the central nervous system, target engagement and tolerability.